Conditions: Plaque Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 96
Healthy volunteers: yes

Brief summary:
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.

Interventions: intervention 1: PF-06700841 oral solution/suspension intervention 2: Placebo intervention 3: PF-06700841 tablet
Intervention descriptions: intervention 1: Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods) intervention 2: Matching placebo given during the single ascending and multiple dose periods intervention 3: PF-06700841 tablet formulation administered during the bioavailability / food effect investigation

Protocol document: